[go: up one dir, main page]

MX2017000184A - Agentes de interaccion enzimatica. - Google Patents

Agentes de interaccion enzimatica.

Info

Publication number
MX2017000184A
MX2017000184A MX2017000184A MX2017000184A MX2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A
Authority
MX
Mexico
Prior art keywords
compounds
agents
enzyme interacting
interacting agents
enzyme
Prior art date
Application number
MX2017000184A
Other languages
English (en)
Inventor
Luke Flynn Bernard
Aurelio Luigi
Vittoria SCULLINO Carmen
Hui Wang Bing
Maxwell Pitson Stuart
Rose Pitman Melissa
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902459A external-priority patent/AU2014902459A0/en
Application filed by Univ Monash filed Critical Univ Monash
Publication of MX2017000184A publication Critical patent/MX2017000184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente divulgación se refiere en general, pero no exclusivamente, a compuestos y a su uso como agentes de interacción enzimática, en particular, agentes que interactúan con una o más enzimas en la ruta de biosíntesis de esfingolípidos. La divulgación se refiere además al uso de tales compuestos como herramientas de investigación, uso en terapia, a composiciones y agentes que comprenden dichos compuestos, y a métodos de tratamiento que usan dichos compuestos.
MX2017000184A 2014-06-26 2015-06-26 Agentes de interaccion enzimatica. MX2017000184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014902459A AU2014902459A0 (en) 2014-06-26 Targeting agents
PCT/AU2015/050358 WO2015196258A1 (en) 2014-06-26 2015-06-26 Enzyme interacting agents

Publications (1)

Publication Number Publication Date
MX2017000184A true MX2017000184A (es) 2017-09-15

Family

ID=54936357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000184A MX2017000184A (es) 2014-06-26 2015-06-26 Agentes de interaccion enzimatica.

Country Status (8)

Country Link
US (1) US9828351B2 (es)
EP (1) EP3160949A4 (es)
JP (1) JP6615876B2 (es)
CN (1) CN107614491A (es)
AU (1) AU2015281799B2 (es)
CA (1) CA2990028A1 (es)
MX (1) MX2017000184A (es)
WO (1) WO2015196258A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112077A1 (en) * 2016-12-13 2018-06-21 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
US12448371B2 (en) * 2019-07-24 2025-10-21 Cincera Therapeutics Pty Ltd Inhibitor compounds
JP2023518446A (ja) * 2020-03-20 2023-05-01 モナッシュ ユニバーシティ ループスを処置するための組成物及び方法
CN116210706B (zh) * 2023-02-03 2024-05-10 河北工业大学 生物碱polyaurine B衍生物在抗植物病毒和病菌中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923661A (en) 1957-03-22 1960-02-02 Irwin Neisler And Co N-[2-(1-phenyl-propyl)]-2, 2, 2-trichloroethylidenimine
FR2073284B1 (es) 1969-12-23 1973-07-13 Ferlux
EP0178035B1 (en) * 1984-05-12 1990-01-03 FISONS plc Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
EP0248523B1 (en) * 1986-05-07 1991-10-16 FISONS plc Pyrazoles
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
FI982268A7 (fi) 1998-10-20 2000-04-21 Jarkko Rautio Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet prodrugit, niiden valmistus ja käyttö
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
EP1432693A2 (en) 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Mch receptor antagonists
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
AU2003245555A1 (en) * 2002-06-17 2003-12-31 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CA2617788A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
WO2007043400A1 (ja) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009043889A2 (en) * 2007-10-04 2009-04-09 Merck Serono S.A. Oxadiazole derivatives
US20090291967A1 (en) * 2008-03-05 2009-11-26 Adherex Technologies, Inc. Small molecule modulators of cell adhesion
PE20091838A1 (es) * 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
HUE025984T2 (hu) * 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
SI2913326T1 (sl) * 2008-05-14 2020-11-30 The Scripps Research Institute Novi modulatorji sfingozinskih fosfatnih receptorjev
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201120016A (en) * 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
CN104144927B (zh) * 2011-12-23 2016-08-24 明治制果药业株式会社 S1p受体调节剂
US9120784B2 (en) * 2012-11-05 2015-09-01 Allergan, Inc. 1,3,4-oxadiazoles-2-thio azetidine derivatives as sphingosine-1 phosphate receptors modulators
KR101559883B1 (ko) * 2013-10-30 2015-10-13 동국대학교 산학협력단 2-아미노치환 옥사디아졸 유도체, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CA2990028A1 (en) 2015-12-30
CN107614491A (zh) 2018-01-19
AU2015281799B2 (en) 2019-11-28
JP6615876B2 (ja) 2019-12-04
US9828351B2 (en) 2017-11-28
US20170190698A1 (en) 2017-07-06
EP3160949A4 (en) 2018-01-17
AU2015281799A1 (en) 2017-01-12
JP2017526733A (ja) 2017-09-14
EP3160949A1 (en) 2017-05-03
WO2015196258A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
AU2019264537A1 (en) Beta-lactamase inhibitors
PH12019502279A1 (en) Cleaning compositions and uses thereof
MX384253B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
MX389228B (es) Composiciones para tratar el cabello.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
MX361862B (es) Composiciones y métodos que comprenden variante de enzima lipolítica.
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX343071B (es) Metodos y composiciones para el control de malezas.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
SG10201804952QA (en) Glucosylceramide synthase inhibitors
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
TW201614069A (en) Inhibitors of MYH7B and uses thereof
SG10201900041VA (en) Meningococcus vaccines
EP4218736A3 (en) Compositions comprising 15-hepe
NZ701463A (en) Anti-phytopathogenic composition
CA2863600A1 (en) Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX2017000184A (es) Agentes de interaccion enzimatica.
WO2014165713A3 (en) Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
BR112017024855A2 (pt) métodos de produção de aldc